Assessing the risk of multiple sclerosis disease-modifying therapies.

Assessing the risk of multiple sclerosis disease-modifying therapies. Expert Rev Neurother. 2019 Jun 14;: Authors: Ayrignac X, Bilodeau PA, Prat A, Girard M, Labauge P, Le Lorier J, Larochelle C, Duquette P Abstract Introduction: The number of immunomodulatory options approved for multiple sclerosis (MS) has increased over the past 24 years, resulting in a better control of the disease. Depending on disease activity, neurologists can now propose treatments with different levels of efficacy, from injectable and oral treatments with modest efficacy, to highly active immunosuppressants and monoclonal antibodies which can be used as induction therapies. Nevertheless, this gain in efficacy has come with an increase in the global burden of treatment-related adverse events, including notably opportunistic infections and autoimmune diseases. Areas covered: The authors have reviewed extensively the existing literature to gain insight into the adverse events associated with each of the disease modifying therapies, so as to help neurologists choose the right treatment for their patients. The authors have reviewed data from phase 3 randomized controlled trials as well as post-marketing surveillance data. The authors classified and summarized the adverse events based on frequency, severity and clinical relevance. Expert opinion: As the number and diversity of these adverse events is expected to increase, careful surveillance of patients under treatment will be even m...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research